Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.

Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, Whitney AM, Stephens DS, Cohn AA, Messonnier NE, Mayer LW.

J Infect Dis. 2010 Apr 15;201(8):1208-24. doi: 10.1086/651505.

PMID:
20199241
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Capsular switching in invasive Neisseria meningitidis, Brazil(1).

Castiñeiras TM, Barroso DE, Marsh JW, Tulenko MM, Krauland MG, Rebelo MC, Harrison LH.

Emerg Infect Dis. 2012 Aug;18(8):1336-8. doi: 10.3201/eid1808.111344.

PMID:
22840713
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine.

Kristiansen PA, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Thomas JD, Clark TA, Laforce M, Caugant DA.

BMC Infect Dis. 2013 Aug 2;13:363. doi: 10.1186/1471-2334-13-363.

PMID:
23914778
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006.

Simões MJ, Cunha M, Almeida F, Furtado C, Brum L.

Epidemiol Infect. 2009 Feb;137(2):161-5. doi: 10.1017/S0950268808001106. Epub 2008 Jul 31.

PMID:
18667108
[PubMed - indexed for MEDLINE]
5.

Capsule switching of Neisseria meningitidis.

Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, Wenger JD, Stephens DS.

Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):271-6.

PMID:
8990198
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex.

Lancellotti M, Guiyoule A, Ruckly C, Hong E, Alonso JM, Taha MK.

Microbes Infect. 2006 Jan;8(1):191-6. Epub 2005 Aug 15.

PMID:
16182586
[PubMed - indexed for MEDLINE]
8.

Genotypic analysis of serogroups other than A, B or C of Neisseria meningitidis in China.

Yang J, Zhang X, Xu X, Xu L, Li M, Yang L, Zhu Y, Shao Z, Liang X, Xu J, Wang Y, Jin Q.

Scand J Infect Dis. 2007;39(9):819-21.

PMID:
17701722
[PubMed - indexed for MEDLINE]
9.

High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil.

Weidlich L, Baethgen LF, Mayer LW, Moraes C, Klein CC, Nunes LS, Rios Sda S, Kmetzsch CI, Rossetti ML, Zaha A.

J Infect. 2008 Oct;57(4):324-31. doi: 10.1016/j.jinf.2008.07.014. Epub 2008 Sep 23.

PMID:
18814914
[PubMed - indexed for MEDLINE]
10.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
[PubMed - indexed for MEDLINE]
11.

Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan.

Chiou CS, Liao JC, Liao TL, Li CC, Chou CY, Chang HL, Yao SM, Lee YS.

BMC Infect Dis. 2006 Feb 15;6:25.

PMID:
16478548
[PubMed - indexed for MEDLINE]
Free PMC Article
12.
13.

Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.

Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, Harrison LH, Jansen KU, Anderson AS.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:68-74. Epub 2011 Jan 1.

PMID:
21245657
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.

Pace D.

Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18. Review.

PMID:
19397410
[PubMed - indexed for MEDLINE]
15.

Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba.

Climent Y, Yero D, Martinez I, Martín A, Jolley KA, Sotolongo F, Maiden MC, Urwin R, Pajón R.

J Clin Microbiol. 2010 Mar;48(3):802-10. doi: 10.1128/JCM.01653-09. Epub 2009 Dec 30.

PMID:
20042619
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.

PMID:
20431379
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.

Bai X, Borrow R.

Expert Rev Vaccines. 2010 Oct;9(10):1203-17. doi: 10.1586/erv.10.116. Review.

PMID:
20923270
[PubMed - indexed for MEDLINE]
18.

Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March 2005.

Alonso JM, Gilmet G, Rouzic EM, Nassif X, Plotkin SA, Ramsay M, Siegrist CA, Stephens DS, Teyssou R, Vogel U.

Vaccine. 2007 May 22;25(21):4125-9. Epub 2007 Mar 19.

PMID:
17449149
[PubMed - indexed for MEDLINE]
19.

[Meningococcal vaccines: from polysaccharide to conjugate vaccines].

Cohen R, Levy C.

Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7. French.

PMID:
22883368
[PubMed - indexed for MEDLINE]
20.

The genetic structure of Neisseria meningitidis populations in Cuba before and after the introduction of a serogroup BC vaccine.

Climent Y, Urwin R, Yero D, Martinez I, Martín A, Sotolongo F, Maiden MC, Pajón R.

Infect Genet Evol. 2010 May;10(4):546-54. doi: 10.1016/j.meegid.2010.02.002. Epub 2010 Feb 13.

PMID:
20156598
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk